BTG ups revenue estimates
BTG, the specialist healthcare company, has upped its full year revenue guidance after a strong showing at its licensing & biotechnology business.
BTG, the specialist healthcare company, has upped its full year revenue guidance after a strong showing at its licensing & biotechnology business.
The firm is raising its revenue estimate for the year ended 31 March 2012 from a forecast of £160m-£165m to £190m-£195m.
Try 6 free issues of MoneyWeek today
Get unparalleled financial insight, analysis and expert opinion you can profit from.
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The company also saw a strong performance from its prostate cancer treatment Zytiga,
Trading at BTC's specialty pharmaceuticals and interventional medicine business divisions had been in line with expectations, it added.
Chief Executive Louise Maki said the company had delivered a strong financial and operating performance across the business.
"Our development programmes are on track and we have made good progress in our interventional medicine business," she added.
-
Pensioners ‘running down larger pots’ to avoid inheritance tax as rule change loomsChanges to inheritance tax (IHT) rules for unused pension pots from April 2027 could trigger an ‘exodus of large defined contribution pension pots’, as retirees spend their savings rather than leave their loved ones with an IHT bill.
-
Why do experts think emerging markets will outperform?Emerging markets were one of the top-performing themes of 2025, but they could have further to run as global investors diversify
